Indirect evidence supports the assumption that antiserotonergic second-generation antipsychotics (SGA) induce and aggravate obsessive–compulsive symptoms (OCS) in schizophrenia. However, multimodal studies assessing the long-term interaction of pharmacotherapy and psychopathology are missing. Over 12 months, we followed-up 75 schizophrenia patients who were classified into two groups according to antipsychotic treatment: clozapine or olanzapine (group I) versus aripiprazole or amisulpride (group II). We applied the Yale Brown Obsessive Compulsive Scale (YBOCS) and investigated between-group changes over time as the primary endpoint. Group I showed markedly higher YBOCS scores at both time points. Repeated measure analyses of variance (ANOVAs) revealed significant interaction effects of group and time (per protocol sample (PP): p=0.006). This was due to persistently high OCS severity within group I, and decreasing YBOCS scores within group II. OCS severity correlated significantly with the negative and general psychopathology subscales of the Positive and Negative Syndrome Scale (PANSS), as well as with depressive symptoms. The progressive differences in OCS severity between our groups support the assumption of differential pharmacodynamic effects on comorbid OCS in schizophrenia. Further studies should address the pathogenetic mechanism, define patients at risk and facilitate early detection as well as therapeutic interventions.
AchimAMMaziadeMRaymondE. (2011) How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull37: 811–821.
2.
Asenjo LobosCKomossaKRummel-KlugeC. (2010) Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev11: CD006633.
3.
BakerRWChengappaKNBairdJW. (1992) Emergence of obsessive compulsive symptoms during treatment with clozapine. J Clin Psychiatry53: 439–442.
4.
BlochMHLanderos-WeisenbergerAKelmendiB. (2006) A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry11: 622–632.
5.
Bradford HillA (2011) The environment and disease: association or causation?Bull World Health Org83: 295–300.
6.
BuckleyPFMillerBJLehrerDS. (2009) Psychiatric comorbidities and schizophrenia. Schizophr Bull35: 383–402.
7.
ChangJSAhnY-MParkHJ. (2008) Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry69: 720–731.
8.
ConnorKMPayneVMGaddeKM. (2005) The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry66: 49–51.
9.
CunillRCastellsXSimeonD (2009) Relationships between obsessive-compulsive symptomatology and severity of psychosis in schizophrenia: a systematic review and meta-analysis. J Clin Psychiatry70: 70–82.
10.
de HaanLBeukNHoogenboomB. (2002) Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. J Clin Psychiatry63: 104–107.
11.
de HaanLHoogenboomBBeukN. (2005) Obsessive–compulsive symptoms and positive, negative, and depressive symptoms in patients with recent-onset schizophrenic disorders. Can J Psychiatry50: 519–524.
12.
de HaanLHoogeboomBBeukN. (2006) Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale in schizophrenia patients. Psychopharmacol Bull39: 25–30.
13.
de HaanLLinszenDHGorsiraR (1999) Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. J Clin Psychiatry60: 364–365.
14.
de HaanLOekenevaAvanAT. (2004) Obsessive-compulsive disorder and treatment with clozapine in 200 patients with recent-onset schizophrenia or related disorders. Eur Psychiatry19: 524.
15.
de HaanLSterkBWoutersL. (2011) The 5-year course of obsessive–compulsive symptoms and obsessive–compulsive disorder in first-episode schizophrenia and related disorders. Schizophr Bull doi:10.1093/schbul/sbr077.
16.
DoldMAignerMLanzenbergerR. S (2011) Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive–compulsive disorder – a meta-analysis of double-blind, randomised, placebo-controlled trials. Fortschr Neurol Psychiatr79: 453–466.
17.
EnglischSEsslingerCIntaD. (2009) Clozapine-induced obsessive compulsive syndromes improve in combination with aripiprazole. Clin Neuropharmacol32: 227–229.
18.
ErbfelderEFaulFBuchnerA (1996) GPOWER: A general power analysis program. Behav Res Methods Instrum Comput28: 1–11.
19.
FentonWSMcGlashanTH (1986) The prognostic significance of obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry143: 437–441.
20.
FontenelleLFLinAPantelisC. (2011) A longitudinal study of obsessive–compulsive disorder in individuals at ultra-high risk for psychosis. J Psychiatr Res45: 1140–1145.
21.
GardnerDMMurphyALO’DonnellH. (2011) International consensus study of antipsychotic dosing. Am J Psychiatry167: 686–693.
22.
HwangMYKimSWYumSY. (2009) Management of schizophrenia with obsessive-compulsive features. Psychiatr Clin North Am32: 835–851.
23.
JooberRBoksaP (2010) Clozapine: a distinct, poorly understood and under-used molecule. J Psychiatry Neurosci35: 147–149.
24.
KaneJHonigfeldGSingerJ. (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry45: 789–796.
25.
KangXSimpsonGM (2010) Clozapine: more side effects but still the best antipsychotic. J Clin Psychiatry71: 982–983.
26.
KimSWShinISKimJM. (2008) Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study. J Clin Psychopharmacol28: 349–352.
27.
KlepschRZaworkaWHandI. (1993) Hamburger Zwangsinventar–Kurzform (HZI-K). Manual [Hamburg Obsessive–Compulsive Inventory – short form (HZI-K)]. Goettingen: Beltz TestGmbH.
28.
KoranLMHannaGLHollanderE. (2007) Practice guideline for the treatment of patients with obsessive–compulsive disorder. Am J Psychiatry164: 5–53.
29.
KwonJSJooYHNamHJ. (2009) Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive–compulsive symptoms. Arch Gen Psychiatry66: 1233–1241.
30.
LinSKSuSFPanCH (2006) Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive/compulsive symptoms. Ther Drug Monit28: 303–307.
31.
LykourasLAlevizosBMichalopoulouP. (2003) Obsessive–compulsive symptoms induced by atypical antipsychotics. A review of the reported cases. Prog Neuropsychopharmacol Biol Psychiatry27: 333–346.
32.
LysakerPHWhitneyKA (2009) Obsessive–compulsive symptoms in schizophrenia: prevalence, correlates and treatment. Expert Rev Neurother9: 99–107.
33.
McEvoyJPLiebermanJAStroupTS. (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry163: 600–610.
34.
MukhopadhayaKKrishnaiahRTayeT. (2009) Obsessive–compulsive disorder in UK clozapine-treated schizophrenia and schizoaffective disorder: a cause for clinical concern. J Psychopharmacol23: 6–13.
35.
MuscatelloMRBrunoAPandolfoG. (2011) Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive–compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol31: 174–179.
36.
NiendamTABerzakJCannonTD. (2009) Obsessive compulsive symptoms in the psychosis prodrome: correlates of clinical and functional outcome. Schizophr Res108: 170–175.
37.
OhoyamaKYamamuraSHamaguchiT. (2011) Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex. Eur J Pharmacol653: 47–57.
38.
PoyurovskyMWeizmanAWeizmanR (2004) Obsessive–compulsive disorder in schizophrenia: clinical characteristics and treatment. CNS Drugs18: 989–1010.
39.
PoyurovskyMZoharJGlickI. (2012) Obsessive–compulsive symptoms in schizophrenia: implications for future psychiatric classifications. Compr Psychiatry53: 480–483.
40.
ReznikIYavinIStryjerR. (2004) Clozapine in the treatment of obsessive–compulsive symptoms in schizophrenia patients: a case series study. Pharmacopsychiatry37: 52–56.
41.
RochaFLHaraC (2006) Benefits of combining aripiprazole to clozapine: Three case reports. Progr Neuropsychopharmacol Biol Psychiatry30: 1167–1169.
42.
Rosa-AlcazarAISanchez-MecaJGomez-ConesaA. (2008) Psychological treatment of obsessive-compulsive disorder: A meta-analysis. Clin Psychol Rev28: 1310–1325.
43.
RyuSOhSChoEY. (2011) Interaction between genetic variants of DLGAP3 and SLC1A1 affecting the risk of atypical antipsychotics-induced obsessive–compulsive symptoms. Am J Med Genet156: 949–959.
44.
ScattonBClaustreYCudennecA. (1997) Amisulpride: from animal pharmacology to therapeutic action. Int Clin Psychopharmacol12(Suppl 2): S29–S36.
45.
SchirmbeckFEsslingerCRauschF. (2011) Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia. Psychol Med41: 2361–2374.
46.
SchirmbeckFNieratschkerVFrankJ. (2012) Polymorphisms in the glutamate transporter gene SLC1A1 and obsessive compulsive symptoms induced by second generation antipsychotic agents. Psychiatr Genet22: 245–252.
47.
SchirmbeckFZinkM (2012) Clozapine-induced obsessive–compulsive symptoms in schizophrenia: A critical review. Curr Neuropharmacol10: 88–95.
48.
SevincokLAkogluAKokcuF (2007) Suicidality in schizophrenic patients with and without obsessive–compulsive disorder. Schizophr Res90: 198–202.
49.
SparshattATaylorDPatelMX. (2010) A systematic review of aripiprazole – dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry71: 1447–1456.
50.
TiihonenJLonnqvistJWahlbeckK. (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).[see comment]. Lancet374: 620–627.
WoodySRSteketeeGChamblessDL (1995) Reliability and validity of the Yale-Brown Obsessive–Compulsive Scale. Behav Res Ther33: 597–605.
54.
YangKCSuTPChouYH (2008) Effectiveness of aripiprazole in treating obsessive compulsive symptoms. Progr Neuropsychopharmacol Biol Psychiatry32: 585–586.
55.
ZinkMEnglischSKnopfU. (2007) Augmentation of clozapine with valproic acid for clozapine-induced obsessive compulsive symptoms. Pharmacopsychiatry40: 202–203.
56.
ZinkMKnopfUKuwilskyA (2006) Management of clozapine-induced obsessive compulsive symptoms in a man with schizophrenia. Austr NZ J Psychiatry41: 293–294.
